Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trialAlexander P. J. Vlaar, Martin Witzenrath, Pieter van Paassen et al.|The Lancet Respiratory Medicine|2022Cited by 143
Clinical features and prognostic factors in Covid-19: A prospective cohort studySanne de Bruin, Lieuwe D. J. Bos, Marian A. van Roon et al.|EBioMedicine|2021Cited by 137
RELAx – REstricted versus Liberal positive end-expiratory pressure in patients without ARDS: protocol for a randomized controlled trialFrederique Paulus, Henrik Endeman, Jasper J. Haringman et al.|Trials|2018Cited by 22
Association between early cumulative fluid balance and successful liberation from invasive ventilation in COVID-19 ARDS patients — insights from the PRoVENT-COVID study: a national, multicenter, observational cohort analysisSanchit Ahuja, Janneke Horn, Harm‐Jan de Grooth et al.|Critical Care|2022Cited by 21
Oxygen Consumption with High-Flow Nasal Oxygen versus Mechanical Ventilation— An International Multicenter Observational Study in COVID–19 Patients (PROXY–COVID)Michela Botta, Marcus J. Schultz, Oriol Caritg et al.|American Journal of Tropical Medicine and Hygiene|2023Cited by 8